Supplementary data from:

Altered microbiome signature in Cushing's syndrome persists beyond remission. A longitudinal and cross-sectional analysis.


German Rubinstein^{1\$}, Ilias Lagkouvardos², Evangelia Intze², Andrea Osswald¹, Stephanie Zopp¹, Leah Theresa Braun¹, Adriana Albani¹, Heike Künzel¹, Anna Riester¹, Felix Beuschlein^{1,4,5}, Martin Reincke¹, Katrin Ritzel¹

The associated article has been submitted to the *The Journal of Clinical Endocrinology & Metabolism*.

Please cite the original article when using these data.

Figure 1: A: Rarefaction curves of both patients' and lean controls samples. **B:** Beta-diversity shown as MDS plot of the microbial profiles from the patients with active CS, CS in remission and obese control patients. **C:** Calinski-Harabasz index showing the optimal number of clusters for Partitioning Around Medoids (PAM) clustering. **D:** MDS plot of microbial profiles of students from years 2016 and 2019 showing an overlap of the samples. **E:** Distances of the groups to their closest medoid. The first panel presents the distances of the 2016's (as three clusters and as a whole) and 2019's students from the closest medoid of the 2016's students. The second panel compares the distances of the students as a whole (2016 and 2019) from the medoids of the 2016's students and the medoids of the combined group (2016 and 2019).

Table 1: Clinical and biochemical data of patients with Cushing's syndrome according to their microbial cluster.



x/yM: distances of the profiles in group x to the closest medoid of group y

Table 1:

	CC -	-at	Ī
	CS active (n=18)		
	Cluster 1	Cluster 2	P-value
	CSA 1	CSA 2	CSA 1 vs.
	(n=11)	(n=7)	CSA 2
	Pituitary: 9	Pituitary: 4	
Etiology of CS	Adrenal: 2	Adrenal: 1	
	Ectopic: 0	Ectopic: 2	
Age [y]	45 ± 15	40 ± 15	0.479
C (5 (0.4)	F: 6	F: 5	0.474
Sex (F/M)	M: 5	M: 2	
Weight [kg]	88 ± 25	76 ± 11	0.536
Height [m]	1.76 ± 0.1	1.65 ± 0.1	0.006
BMI [kg/m²]	28.3 ± 7.4	27.7 ± 3.8	0.724
Waist to Hip ratio	0.93 ± 0.1	0.92 ± 0.08	0.791
Card	liovascular risk facto	ors	
Prediabetic state or Diabetes mellitus	4/11	4/7	0.387
Glucose [mg/dl]	108 ± 49	103 ± 29	0.733
HbA1c [%]	5.97 ± 0.85	5.9 ± 1	0.930
Hypertension	8/11	6/7	0.518
Systolic Blood Pressure [mmHg]	131 ± 19	158 ± 35	0.069
Diastolic Blood Pressure [mmHg]	86 ± 16	105 ± 19	0.069
Triglycerides [mg/dl]	88 ± 28	104 ± 34	0.404
Cholesterol [mg/dl]	193 ± 43	184 ± 38	0.591
LDL-Cholesterol [mg/dl]	119 ± 40	115 ± 32	0.733
HDL-Cholesterol [mg/dl]	60 ± 10	53 ± 15	0.350
Qu	ality of Life Surveys	S	
BDI I – II	17.75 ± 11.6	11.83 ± 7.83	0.228
Tuebingen CD-25	32.6 ± 19.2	39.2 ± 15	0.622
Cushing QoL	48.5 ± 25.8	53 ± 21.8	0.573
Inf	fection/Inflammation	1	1
Infectious complications		=	0.197
(with inpatient treatment)	0/11	1/7	0.177
Infectious complications	3/11	2/7	0.952
(with outpatient treatment)			
			0.425

CRP [mg/dl]	0.17 ± 0.21	0.73 ± 0.89	0.044	
Biochemical testing of CS				
Baseline Cortisol [µg/dl]	23.5 ± 10.7	29.3 ± 16.5	0.425	
Cortisol after 1mg Dexamethasone [µg/dl]	14.5 ± 11	18.3 ± 12	0.659	
LSST [ng/ml]	9.2 ± 9.7	68.7 ± 108.5	0.056	
UFC [μg/24h]	422 ± 265	2043 ± 3883	0.179	